Physician profile
Javier Guzman
NPI 1306696489
$3,763.56
in general payments reported to CMS, 2019-2025
13 companies · $3,222 in 2025
The $3,222 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $542 · 2025: $3,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,763.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,178.26 | 2025 | Apretude, Dovato, Cabenuva |
| Gilead Sciences, INC. | $902.70 | 2024-2025 | Yeztugo, Descovy, Biktarvy |
| Astrazeneca Pharmaceuticals Lp | $317.94 | 2024-2025 | Breztri, Farxiga |
| Pfizer INC. | $266.96 | 2024-2025 | |
| Glaxosmithkline, LLC. | $264.85 | 2025 | Shingrix, Arexvy, Nucala |
| Novo Nordisk INC | $220.48 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $208.98 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Optinose US, INC. | $125.00 | 2025 | |
| Lilly USA, LLC | $89.75 | 2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $75.12 | 2024-2025 | Pifeltro, Capvaxive, Vaxneuvance |
| Theratechnologies INC. | $50.84 | 2024-2025 | Egrifta, Trogarzo |
| Kowa Pharmaceuticals America, INC. | $40.86 | 2025 | Zoryve |
| Abbvie INC. | $21.82 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.